Managers

Trail Mix Ventures ropes in $5.3 mln for inaugural fund

Trail Mix Ventures has raised $5.3 million for its debut fund, according to an SEC filing. The target is $15 million. The New York-based venture firm invests in " the future of living well."

SomaLogic snaps up $200 mln

Boulder, Colorado-based SomaLogic, a provider of health management insights, has raised $200 million in funding. The lead investor was iCarbonX with participation from Nan Fung Life Sciences and Madryn Asset Management.

Vaccine developer Themis pockets Series C funding

Themis, an Austrian vaccine developer, has raised 10 million euros in Series C financing. Global Health Investment Fund was the lead investor with participation from aws Gruenderfonds, Omnes Capital, Ventech and Wellington Partners Life Sciences. In addition to the funding, Glenn Rockman, a partner at GHIF, will join Themis’ supervisory board.

Cityblock Health scores $20.8 mln Series A

Brooklyn-based Cityblock Health, an urban healthcare company, has secured $20.8 million in Series A funding. Maverick Ventures led the round with participation from Thrive Capital and Alphabet's Sidewalk Labs.

French biotech firm Acticor Biotech fetches funding

Paris-based Acticor Biotech, a biotech company involved in the acute phase of thrombotic diseases, has raised 1.7 million euros in funding. Primer Capital led the round.

Stoke Therapeutics hauls in $40 mln Series A

Bedford, Massachusetts-based Stoke Therapeutics Inc, which works to increase gene expression to treat diseases caused by genetic insufficiency, has raised $40 million in Series A financing. Apple Tree Partners led the round.

Recros Medica inks $9 mln

Recros Medica Inc, a medical aesthetic device company, has secured $9 million in financing. The investors included Longwood Fund. Also, the company has added Dr. Christoph Westphal and Mark Kerslake to its board of directors.

Personal Genome Diagnostics snags $75 mln Series B

Personal Genome Diagnostics Inc has raised $75 million in Series B financing. Bristol-Myers Squibb and New Enterprise Associates led the round with participation from other investors that included Inova Strategic Investments, Helsinn Investment Fund, Windham Venture Partners and Maryland Venture Fund. Based in Baltimore, Personal Genome Diagnostics is a developer of regulated tissue-based and liquid biopsy genomic products for laboratories.

Belgian biotech company Rewind Therapeutics picks up Series A funding

Rewind Therapeutics, a Belgian biotech company, has closed 15.2 million euros in Series A financing. The backers were Boehringer Ingelheim Venture Fund, Merck Ventures BV, Participatiemaatschappij Vlaanderen, KU Leuven's Centre for Drug Design and Discovery and KU Leuven Gemma Frisius Fonds.

Neurogastrx rakes in $45 mln Series A

Neurogastrx, Inc, a private biopharmaceutical company focused on developing therapies for gastrointestinal disorders affecting the enteric nervous system, has secured $45 million in Series A financing. The lead investors were 5AM Ventures, OrbiMed Advisors and venBio Partners. In conjunction with the financing, Jim O'Mara has been appointed CEO while Klaus Veitinger, a venture partner at OrbiMed Advisors, will become chairman of the board. Also, David Allison of 5AM Ventures, Aaron Royston of venBio and Kevin Koch will be joining the board of directors.